Compare BioNTech SE - ADR (BNTX) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Ralph Lauren Corp — how do they compare? BioNTech SE - ADR trades at $90.28 (market cap $22.86B), while Ralph Lauren Corp trades at $373.42 (market cap $21.96B). The key difference: BioNTech SE - ADR and Ralph Lauren Corp are close in size by market cap, and Ralph Lauren Corp pays a 1.01% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | RL | |
|---|---|---|
Market Cap | $22.86B | $21.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $414.25 |
52-Week Low | $83.89 | $283.34 |
Enterprise Value | $6.53B | $22.90B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Ralph Lauren (RL) trades at $374.49, down 5.17% on the day, showing bearish technical momentum despite strong fundamentals. The company demonstrates robust financial performance with consistent earnings beats, including Q1 2026 EPS of $2.80 beating expectations of $2.55. Revenue growth accelerated to $7.08 billion in 2025 with net income margin expanding to 10.49%. Analyst consensus remains strongly bullish with 66% buy ratings and a $446.25 price target representing 19% upside potential.
The stock presents a compelling growth opportunity with strong brand momentum and digital expansion driving performance, though premium valuation metrics and technical bearish signals warrant caution. Key risks include macroeconomic sensitivity and competitive pressures in the apparel sector, while institutional sentiment remains positive given the company's execution on its Next Great Chapter strategy and Asia growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
